Electrophysiologic monitoring of the effects of soluble virulence factors produced by Escherichia coli infection in urine

Urology

Volumn 48, Issue 3, 1996, Pages 389-392

  Tay, Howard ^a,b   Parsons, C Lowell ^a   Stein, Paul C ^a  

^a UCSD MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSAMINOGLYCAN; VIRULENCE FACTOR;

ANIMAL TISSUE; ARTICLE; BACTERIAL VIRULENCE; BLADDER MUCOSA; BLADDER PERMEABILITY; CONTROLLED STUDY; CYSTITIS; ELECTROPHYSIOLOGY; ESCHERICHIA COLI; FEMALE; NONHUMAN; PRIORITY JOURNAL; RABBIT;

EID: 0030248670     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00209-9     Document Type: Article

References (15)

1. Duguid JP, and Anderson ES: Terminology of bacterial fimbriae, or pili, and their types. Nature 215: 89-90, 1967.
2. Domingue GJ, Roberts JA, Laucirica R, Ratner MH, Bell DP, Suarez GM, Kallenius G, and Svenson S: Pathogenic significance of P-fimbriated Escherichia coli in urinary tract infection. J Urol 133: 983-989, 1985.
3. Hagberg L, Jodal U, Korhonen TK, Lidin-Janson G, Lindberg U, and Svanborg Eden C: Adhesion, hemagglutination, and virulence of Escherichia coli causing urinary tract infections. Infect Immun 31: 564-570, 1981.
4. Parsons CL, Greenspan C, Moore S, and Mulholland S: Role of surface mucin in primary antibacterial defense of bladder. Urology 9: 48-52, 1977.
5. Parsons CL, Stauffer C, and Schmidt JD: Bladder-surface glycosaminoglycans: an efficient mechanism of environmental adaptation. Science 208: 605-607, 1980.
6. Parsons CL, Greenspan C, and Mulholland SG: The primary antibacterial defense mechanism of the bladder. Invest Urol 13: 72-76, 1975.
7. Parsons CL, Stauffer CW, and Schmidt JD: Reversible inactivation of bladder surface glycosaminoglycan antibacterial activity by protamine sulfate. Infect Immun 56: 1341-1343, 1988.
8. Parsons CL: Prevention of urinary tract infection by the exogenous glycosaminoglycan sodium pentosanpolysulfate. J Urol 127: 167-169, 1982.
9. Mostafavi M, Stein PC, and Parsons CL: Production of soluble virulence factor by Escherichia coli. J Urol 153: 1441 -1443, 1995.
10. Tzan CJ, Berg J, and Lewis SA: Effect of protamine sulfate on the permeability properties of the mammalian urinary bladder. J Membr Biol 133: 227-242, 1993.
11. Turnbull GJ, and Fellows GJ: Permeability of the urinary bladder of the rabbit. Eur J Clin Biol Res 17: 745-749, 1972.
12. Parsons CL, Boychuk D, Jones S, Hurst R, and Callahan H: Bladder surface glycosaminoglycans: an epithelial permeability barrier. J Urol 143: 139-142, 1990.
13. Menter JM, Hurst RE, Nakamura N, and West SS: Thermodynamics of mucopolysaccharide-dye binding: III. Thermodynamic and cooperativity parameters of acridine orange-heparin system. Biopolymers 18: 493-505, 1979.
14. Menter JM, Hurst RE, Corliss DA, West SS, and Abrahamson EW: Structural basis for the anticoagulant activity of heparin: II. Relationship of anticoagulant activity to the thermodynamics of fluorescence fading kinetics of acridine orange-heparin complexes. Biochemistry 18: 4288-4292, 1979.
15. Parsons CL, Stein PC, Bidair M, and Lebow D: Abnormal sensitivity to intravesical potassium in interstitial cystitis and radiation cystitis. Neurourol Urodyn 13: 515-520, 1994.